Editorial
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Surg. Feb 27, 2025; 17(2): 100257
Published online Feb 27, 2025. doi: 10.4240/wjgs.v17.i2.100257
Programmed cell death receptor 1 inhibitor Pembrolizumab in the treatment of advanced gastric cancer
Xue-Mei Yi, Hong-Qiao Cai, Yan Jiao
Xue-Mei Yi, Department of Second Operation Room, The First Hospital of Jilin University, Changchun 130021, Jilin Province, China
Hong-Qiao Cai, Yan Jiao, Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun 130021, Jilin Province, China
Author contributions: Yi XM contributed to the discussion and design of the manuscript; Yi XM and Cai HQ contributed to the writing, and editing the manuscript, illustrations, and review of literature; Jiao Y designed the overall concept and outline of the manuscript; all of the authors read and approved the final version of the manuscript to be published.
Supported by Jilin Provincial Natural Science Foundation, No. YDZJ202401650ZYTS.
Conflict-of-interest statement: All authors declare no conflict of interest in publishing the manuscript.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yan Jiao, MD, PhD, Doctor, Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, The First Hospital of Jilin University, No. 1 Xinmin Street, Changchun 130021, Jilin Province, China. lagelangri1@126.com
Received: August 11, 2024
Revised: December 18, 2024
Accepted: December 25, 2024
Published online: February 27, 2025
Processing time: 163 Days and 20 Hours
Core Tip

Core Tip: In the past decade, programmed cell death receptor 1 (PD-1) inhibitors have shown significant anti-tumor effects and good safety in the treatment of various malignant tumors such as melanoma and non-small cell lung cancer. Multiple studies on advanced gastric cancer have shown that the combination therapy of PD-1 inhibitors can improve the efficacy. Pembrolizumab combined with chemotherapy or human epidermal growth factor receptor 2 targeting therapy have showed improved prognosis. In the future, it is important to explore the reasonable treatment sequence and dosage, to maximize the efficacy of combination therapy.